grant

Redirecting T-cells for immunotherapy of leukaemia and lymphoma by the expression of a CD19-specific chimeric antigen receptor using the PiggyBac transposon gene modification system [ 2012 - 2015 ]

Also known as: Genetic modification of immune cells to target lymphoma and leukaemia

Funded by National Health and Medical Research Council
Managed by The University of Sydney
Managed by University of Sydney
Provided by   National Health and Medical Research Council

Research Grant

[Cite as https://purl.org/au-research/grants/nhmrc/1029701]

Researchers: Dr Kenneth Micklethwaite (Principal investigator)

Brief description Most lymphomas respond to therapy but then relapse. Immune cells can attack and kill virus related lymphomas. However, most lymphomas are NOT virus related. We will create immune cells targeting these virus negative lymphomas by inserting artificial receptors into the immune cells. These receptors attach to the lymphoma and activate the immune cells. The immune cells will home to the lymphoma, kill lymphoma cells and persist in the body for many years, preventing lymphoma relapse.

Funding Amount $AUD 374,876.75

Funding Scheme Project Grants

Notes New Investigator Grant

Click to explore relationships graph
Help

Related Organisations

Related People

Subjects
Cardiorespiratory Medicine and Haematology | Haematology | Medical and Health Sciences | cytotoxic T lymphocytes (CTL) | gene transfer | lymphocytic leukaemia | non-Hodgkin lymphoma | tumour immunotherapy | tumour-specific targeting |
Identifiers
Viewed: [[ro.stat.viewed]]
Saved to MyRDA Save to MyRDA